MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-03-2026
Agilent Technologies Revenue 2011-2026 | A
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Agilent Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 6.32 B | 5.34 B | 5.16 B | 4.91 B | 4.47 B | 4.2 B | 4.04 B | 6.98 B | 6.78 B | 6.86 B | 6.62 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.98 B | 4.04 B | 5.61 B |
Quarterly Revenue Agilent Technologies
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.8 B | - | 1.74 B | 1.68 B | - | 1.58 B | 1.66 B | 1.72 B | 1.67 B | - | - | 1.61 B | 1.55 B | - | 1.59 B | 1.52 B | 1.36 B | 3.86 B | 1.26 B | 1.24 B | 1.28 B | 3.8 B | 1.27 B | 1.24 B | 1.21 B | 3.62 B | 1.2 B | 1.21 B | 1.07 B | 3.28 B | 1.11 B | 1.1 B | 1.03 B | 3.09 B | 1.04 B | 1.02 B | 1.03 B | 3 B | 1.01 B | 963 M | 1.01 B | 3 B | 1.01 B | 988 M | 1.68 B | 5.06 B | 1.65 B | 1.73 B | 1.64 B | 5.09 B | 1.72 B | 1.73 B | 1.52 B | 4.89 B | 1.69 B | 1.68 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.09 B | 963 M | 1.87 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
332 M | $ 23.75 | -3.85 % | $ 660 M |  USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Neogen Corporation
NEOG
|
895 M | $ 9.15 | -2.09 % | $ 1.98 B | USA |
 |
Co-Diagnostics
CODX
|
622 K | $ 1.57 | -3.68 % | $ 2.09 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 25.87 | -4.63 % | $ 20 B |  Niderland |
 |
CareDx, Inc
CDNA
|
380 M | $ 18.76 | -14.38 % | $ 1 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Personalis
PSNL
|
84.6 M | $ 5.14 | -6.64 % | $ 305 M | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 14.8 | -3.27 % | $ 447 M | USA |
 |
Illumina
ILMN
|
4.37 B | $ 122.36 | -3.59 % | $ 19.5 B | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 164.68 | -1.27 % | $ 8.16 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Trinity Biotech plc
TRIB
|
61.6 M | $ 0.6 | -1.75 % | $ 61.9 M |  Irlanda |
 |
Guardant Health
GH
|
982 M | $ 80.74 | -2.83 % | $ 10.1 B | USA |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 80.56 | -3.58 % | $ 5.44 B | USA |
 |
Twist Bioscience Corporation
TWST
|
377 M | $ 56.42 | -4.62 % | $ 3.37 B | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
38.7 M | $ 1.99 | 2.9 % | $ 8.8 M | USA |
 |
Senseonics Holdings
SENS
|
35.3 M | $ 6.61 | -7.94 % | $ 276 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B | Niderland |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 414.07 | 1.05 % | $ 11.9 B | USA |
 |
Biomerica
BMRA
|
5.31 M | $ 2.16 | -1.22 % | $ 4.96 M | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 117.5 | 14.65 % | $ 9.69 B | Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 256.65 | -1.12 % | $ 21.4 B | USA |
 |
NeoGenomics
NEO
|
727 M | $ 8.49 | -5.88 % | $ 1.09 B | USA |
 |
National Research Corporation
NRC
|
137 M | $ 15.61 | -7.33 % | $ 349 M | USA |
 |
Myriad Genetics
MYGN
|
824 M | $ 4.62 | -4.55 % | $ 428 M | USA |
 |
Natera
NTRA
|
820 M | $ 192.71 | -3.73 % | $ 19 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 190.26 | -2.46 % | $ 21.1 B | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
508 M | $ 16.15 | -2.99 % | $ 174 M | China |
 |
OpGen
OPGN
|
5.2 M | - | -16.95 % | $ 1.54 M | USA |
 |
Organovo Holdings
ONVO
|
144 K | - | -2.3 % | $ 19.4 M | USA |